MicroRNAs in colorectal cancer: from diagnosis to targeted therapy.
نویسندگان
چکیده
Colorectal cancer (CRC) is one of the major healthcare problems worldwide and its processes of genesis include a sequence of molecular pathways from adenoma to carcinoma. The discovery of microRNAs, a subset of regulatory non-coding RNAs, has added new insights into CRC diagnosis and management. Together with several causes of colorectal neoplasia, aberrant expression of oncomiRs (oncogenic and tumor suppressor miRNAs) in cancer cells was found to be indirectly result in up- or down-regulation of targeted mRNAs specific to tumor promoter or inhibitor genes. The study of miRNAs as CRC biomarkers utilizes expression profiling methods from traditional tissue samples along with newly introduced non-invasive samples of faeces and body fluids. In addition, miRNAs could be employed to predict chemo- and radio-therapy responses and be manipulated in order to alleviate CRC characteristics. The scope of this article is to provide a comprehensive review of scientific literature describing aberrantly expressed miRNAs, and consequently dysregulation of targeted mRNAs along with the potential role of miRNAs in CRC diagnosis and prognosis, as well as to summarize the recent findings on miRNA-based manipulation methods with the aim of advancing in anti-CRC therapies.
منابع مشابه
A review on miRNAs as new biomarkers for colorectal cancer
Background & Objective: Since colorectal cancer does not often have phenotypic symptoms in the early stages, the study of biomarkers for the diagnosis and prognosis of the tumor is very important. MicroRNAs are one of the most important biomarkers which attract the attention of many researchers due to a variety of reasons, including their non-invasive nature; these molecules are a group of non-...
متن کاملارزیابی فراوانی جهشهای ژن KRAS در بیماران ایرانی مبتلا به سرطان کولورکتال
Background: Kirsten rat sarcoma (KRAS) gene is a target of genetic alterations which are diagnostic and prognostic biomarkers in patients with metastatic colorectal cancer who are treated with monoclonal anti-EGFR antibodies such as cetuximab and panitumumab. KRAS mutations are seen in 35-42% of patients with colorectal cancer. The high frequency of these mutations in colorectal cancer represen...
متن کاملنقش microRNA-21 در سرطان کولورکتال و قابلیت آن به عنوان یک بیومارکر پیش بینی کننده، تشخیصی و پیش آگهی: مقاله مروری
Colorectal cancer (CRC) is one of the most common types of cancers worldwide. Despite the improved therapeutic and diagnostic strategies and screening programs, morbidity and mortality of CRC is still considerable. Currently, most common approaches for diagnosis of CRC are colonoscopy and fecal occult blood test (FOBT). Because of the invasive nature of colonoscopy and low sensitivity of FOBT, ...
متن کاملMicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapies
Colorectal cancer (CRC) is still one of the five most leading cancer-related death which have one million new cases every year (Pourhoseingholi, 2012; Siegel et al., 2012). Although since mid-1980’s the number of CRCrelated death has been decreasing due to the increased awareness and progresses in screening approaches, the prognosis of patients with metastatic CRC remains unknown (Terzic et al....
متن کاملEpigenetics in diagnosis of colorectal cancer
Colorectal cancer (CRC) is a third most common epithelial carcinoma. CRC is known to develop from the early precancerous lesion to full blown malignancy via definite phases due to cumulative mutations and aberrant methylation of number of genes. The use of serum biomarkers that is non-invasive to discriminate cancer patients from healthy persons will prove to be an important tool to improve the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Asian Pacific journal of cancer prevention : APJCP
دوره 15 17 شماره
صفحات -
تاریخ انتشار 2014